ClinicalTrials.gg
Not yet recruitingNCT06125899INDIGOUpdated Nov 9, 2023

Protocol for a Feasibility Cluster Randomised Controlled Trial of a Home-based Depression Care for Older People Delivered by Lay Providers in Nigeria

An interventional study of emhGAP-Age in Depression in Old Age, sponsored by University of Ibadan. Not yet recruiting. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by University of Ibadan · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The aim of this hybrid (Effectiveness-Implementation) cluster randomised controlled clinical trial is to test the feasibility of implementing an age-appropriate electronic version of the WHO Mental Health Gap Action Programme Intervention Guide (emhGAP-Age) in routine home-based care of older Nigerians with depression. The main questions it aims to answer are:

  1. Whether the emhGAP-Age demonstrate sufficient signals of effectiveness in the identification and home management of late life depression to permit for further exploration in a fully powered clinical trial?
  2. What are the logistical, programmatic, and operational requirements for a home-delivered emhGAP-Age in a sample of older people with depression in Nigeria? Consenting older participants with depression in the intervention arm will receive treatment based on emhGAP-Age which consists of;

    • Adapted electronic generic version of the WHO Mental Health Gap Action Programme Intervention Guide (emhGAP-IG)
    • Adapted Problem-Solving Therapy (PST-PC)
    • Support/supervision of providers
    • Links to social support resources. Researchers will compare with treatment based on the basic specification in the generic emhGAP-IG (consisting of basic psychoeducation and stress reduction) for effects on depression remission.
02

Conditions studied

  • Depression in Old Age

Browse trials for

03

In context

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 110 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of Ibadan is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 60 years,
  2. PHQ-9 score of ≥11 during routine consultation

Exclusion criteria

Exclusion Criteria:

  1. Severe co-morbidity requiring urgent attention.
  2. Severe cognitive impairment/dementia (Community Screening Instruments for Dementia score≤ 20) .
  3. Active suicidal intention.
  4. Evidence of bipolar/psychosis/severe substance use disorders.
  5. Planning to move out of the study catchment area within 6 months.
  6. Refusing/lacking capacity to consent/accent
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Age emhGAP-IG

    * Adapted emhGAP-IG; * Adapted Problem-Solving Therapy (PST-PC) * Support/supervision of lay providers * Links to social support resources.

    Behavioral: emhGAP-Age

  • Active comparator
    Generic emhGAP-IG

    Psychoeducation and stress reduction

    Behavioral: emhGAP-Age

Interventions

  • BehavioralemhGAP-Age

    * Adapted emhGAP-IG; * Adapted Problem-Solving Therapy (PST-PC) * Support/supervision of lay providers * Links to social support resources.

06

What researchers measure

Primary outcomes

  1. Depression remission

    Patient Health Questionnaire (PHQ-9) score \< 6

    Time frame: At six months post trial entry

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for Jul 2025, 17 months later.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 17 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2023
First posted
Nov 9, 2023
StartEst.
Feb 2024
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06125899
Lead sponsor
University of Ibadan
Responsible party
Akin Ojagbemi (Senior Lecturer, University of Ibadan) — Principal investigator
First posted
Nov 9, 2023
Start date
Feb 2024 (estimated)
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Nov 9, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion